Premium
Aspects on Radionuclide Therapy in Malignant Pheochromocytomas
Author(s) -
FORSSELLARONSSON EVA,
BERNHARDT PETER,
WÄNGBERG BO,
KÖLBY LARS,
NILSSON OLA,
AHLMAN HÅKAN
Publication year - 2006
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1196/annals.1353.052
Subject(s) - radionuclide therapy , medicine , scintigraphy , radiation therapy , octreotide , adjuvant therapy , nuclear medicine , radiology , chemotherapy , somatostatin
Abstract: Malignant pheochromocytomas/paragangliomas (PCs/PGs) often have distant metastases to the skeleton, liver, and lungs. Radionuclide therapy is valuable for treatment of disseminated tumor disease and could be used as adjuvant therapy after surgery. Patients with local and/or distant metastases of PC/PG should be investigated preoperatively by scintigraphy using both 123 I‐MIBG and 111 In‐DTPA‐D‐Phe 1 ‐octreotide, to evaluate the possibilities for radionuclide therapy (i.e., a dosimetric estimation of radiation dose to the tumor tissue versus critical normal tissues). Individual patient dose‐planning should be performed. For patients in whom positive therapeutic effects are anticipated radionuclide therapy can be applied. Therapy with both 131 I‐MIBG and 177 Lu‐octreotate might be favorable in individual patients with lesions visualized by both metaiodobenzylguanidine (MIBG) and octreotide scintigraphy with enhanced therapeutic effects and reduced side effects.